Kornimate/medical-research-clean huggingface dataset:
anticoagulants for pfo patients

Conditions: Patent Foramen Ovale

Summary: patients who underwent both bubble transcranial doppler (bubble-tcd) and transoesophageal echocardiography (tee) at our institution were consecutively enrolled in this real-world case-control study from august 2016 through august 2023. the patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). in cases with mild-shunt (small-size) pfo, post-procedural anticoagulation or pfo closure was administered. subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality.


Eligibility criteria:
inclusion criteria: 1. verified pfo diagnosis through tee, bubble-tcd, or contrast echocardiography of the right heart; 2. ages range between 16 and 65; 3. no restrictions on sexual orientation; 4. stroke patients with cryptogenic strokes as per the toast classification; 5. no other likely causes for migraines, with the exception of pfo; 6. no multiple risk factors for cerebrovascular disease, such as hypertension, diabetes, or smoking. exclusion criteria: * 1)severe, acute, or life-threatening conditions including acute cardio-cerebrovascular diseases, significant organ failure, or infections; 2)magnetic resonance imaging (mri) contraindications, especially with contrast enhancement; 3) presence of cerebral artery stenosis, internal carotid artery stenosis, or atherosclerosis; 4) hypercoagulability or venous thrombosis; 5) contraindications associated with pfo closure and anticoagulants; 6) obstructive sleep apnea.

Keywords: patent foramen ovale migraine stroke
effect of bilateral quadratus lumborum block for pain relief in patients with cesarean section

Conditions: Caesarean Section; Spinal Anesthesia; Quadratus Lumborum Block; Analgesia

Summary: cesarean section commonly induces moderate to severe pain for 48 hours. these patients have additional compelling reasons to provide adequate pain relief as early mobilization is a key factor to prevent the risk of thromboembolic event which is increased during pregnancy. beside these, patients need to be pain free to takecare for their newborn and breastfeed them. poorly controlled pain after cesarean section also increases risk of chronic pain and postpartum depression. intrathecal morphine is considered the "gold standard" for postoperative pain relief after cesarean delivery. the duration of analgesic effect of morphine extend to 12-24 hours. its widespread use is due to its favorable pharmacokinetic profile, ease of administration and low cost. although intrathecal morphine is highly effective, its use is associated with undesirable adverse effect particularly nausea, vomiting and pruritus which reduce overall patients' satisfaction. more serious complication is the risk of delayed maternal respiratory depression. the quadratus lumborum block was first described in 2007 which demonstrates a spread to the paravertebral space, thus leads to a more extensive block to t5-l1 nerve branches and a long lasting block with the potential to provide visceral pain relief. therefore, this block has an evolving role in postoperative analgesia for many lower abdominal surgeries. as the safety is concerned, there has been one report of a patient with unilateral hip flexion and knee extension weakness leading to unplanned overnight admission following lateral quadratus lumborum block after laparoscopic gynaecological operation. if the result favors effective, it will have the advantage of a combination with intrathecal opioid to prolong the pain free period after cesarean section which has about 4,000 cases per year.


Eligibility criteria:
inclusion criteria: * all singleton pregnant women with gestation of at least 37 weeks scheduled for elective cesarean section with american society of anesthesiologists (asa) physical status 1 or 2 exclusion criteria: 1. refuse to receive spinal block 2. allergy to drugs used in research: morphine, local anesthetic drug and paracetamol 3. abnormal coagulopathy: congenital coagulopathy or who used anticoagulants 4. platelet dysfunction or thrombocytopenia 5. distorted anatomical structures of lumbar spines 6. systemic infection or local infection at both flank areas which are the punctures sites for quadratus lumborum block 7. unable to comprehend or use the verbal rating pain scoring system or patient-controlled analgesia

Keywords: caesarean section spinal anesthesia quadratus lumborum block postoperative pain intrathecal morphine
the efficacy of progestins in treatment of functional ovarian cyst

Conditions: Functional Ovarian Cyst; Progesterone

Summary: the aim of this study is to determine whether the use of progesterone only pills has a beneficial effect over the expectant management of functional ovarian cyst or not , through a sample of female patients within the reproductive years

an ovarian cyst is a common gynecological problem and is divided into 2 main categories; physiological and pathological in relative frequency, functional cysts account for about 24% of all ovarian cysts, benign cysts 70% and malignant 6% functional cysts are the most common masses seen in the premenopausal ovary and are estimated to affect 8%-20% of reproductive-aged women pain or discomfort in the lower abdomen severe pain from torsion (twisting) or rupture - cyst rupture is characterized by sudden, sharp, unilateral pelvic pain; this can be associated with trauma, exercise, or coitus. cyst rupture can lead to peritoneal signs, abdominal distention, and bleeding (which is usually self-limited) discomfort with intercourse, particularly deep penetration changes in bowel movements such as constipation pelvic pressure causing tenesmus or urinary frequency menstrual irregularities precocious puberty and early menarche in young children abdominal fullness and bloating indigestion, heartburn, or early satiety hyperpyrexia - this may result from some complications of ovarian cysts, such as ovarian torsion adnexal or cervical motion tenderness in current clinical practice , gynecologists treat functional ovarian cysts with either oral contraceptive pills or expectant management alone. we presume using progesterone only pills for treatment of functional ovarian cyst

Eligibility criteria:
inclusion criteria: * female patients at reproductive age (18-44) menstruating ovarian cyst (a cyst 3-10 cm in diameter, unilateral , unilocular ,clear content) bmi : patients with normal bmi (18.5-24.9) and overweight (25-29.9) included exclusion criteria: * exclusion criteria are ovarian payhology (dermoid, endometriosis or malignancies) complicated cyst (rupture, torsion) patients receiving hormonal treatment for the previous 3 cycles history of surgical removal of ovarian cyst comorbidities like uncontrolled dm ,hypertension and tuberculosis
trilaciclib (g1t28), a cdk 4/6 inhibitor, in combination with etoposide and carboplatin in extensive stage small cell lung cancer (sclc)

Conditions: Small Cell Lung Cancer

Summary: this is a study to investigate the potential clinical benefit of trilaciclib (g1t28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage sclc. the study consists of 2 parts: a limited open-label, dose-finding portion (part 1), and a randomized double-blind portion (part 2). both parts include 3 study phases: screening phase, treatment phase, and survival follow-up phase. the treatment phase begins on the day of first dose with study treatment and completes at the post-treatment visit. approximately, 90 patients will be enrolled in the study; 20 patients in the part 1 and 70 patients in the part 2 portion.


Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥18 years * unequivocally confirmed diagnosis of sclc by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry * at least 1 target lesion that is unirradiated and measurable by recist, version 1.1 * eastern cooperative oncology group (ecog) performance status of 0 - 2 * adequate organ function exclusion criteria: * prior chemotherapy for extensive-stage sclc * presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids. * uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure * known history of stroke or cerebrovascular accident within 6 months prior to enrollment * other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol * concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) * receipt of any investigational medication within 4 weeks prior to enrollment

Keywords: small cell lung cancer cdk 4/6 inhibitor
natural versus hrt cycles in frozen embryo replacement treatment

Conditions: Infertility

Summary: frozen embryo replacement (fer)is a fertility treatment by which stored embryos from a fresh ivf treatment cycle are thawed and transferred into the uterus. frozen embryos can be replaced either in the middle of a natural menstrual cycle (natural fer) or in a cycle where the woman takes drugs to suppress her own hormones, and then takes hormone replacement therapy (hrt) to prepare her uterus for the transfer of embryos(hrt - fer). both are widely used methods of fertility treatment. however, to date no well designed studies have been reported in which the two methods have been compared. this study aims to compare the two treatments in order to establish the best treatment protocol. the study design is a single centre open randomized controlled trial funded by the oxford fertility unit. 100 women who are considering fer treatment at the oxford fertility unit and are eligible for the study will be recruited. after giving their written consent they will be randomised to one of 2 groups: natural fer and hrt fer. patients in both groups will be asked to attend one initial visit, which is additional to patients not taking part in the study. subsequent visits will depend on the treatment group but will not be additional for study participants. all visits requiring ultrasound will involve recording 3-d measurements, which increases the length of each visit by approximately 10 minutes. a patient satisfaction questionnaire would be completed at the end of the cycle. a urinary pregnancy test is performed at home 2 weeks following the embryo transfer visit. if this is positive then further visits to the unit are arranged to confirm the clinical pregnancy. inclusion in the study would not increase the length of time of either treatment cycle. follow up would extend to obtaining pregnancy outcome information.


Eligibility criteria:
inclusion criteria: * women attending oxford fertility unit planning a frozen embryo replacement cycle. * willing and able to give informed consent for participation in the study. * age at original fresh ivf cycle \< 40 years old. * at least 3 embryos frozen in storage * first or second fer cycle * regular ovulatory menstrual cycles, confirmed by luteal progesterone levels \>16nmol/l and with cycle length \< 35 days. exclusion criteria: * women with irregular cycles (outlined above), including amenorrhoea or oligomenorrhoea. * co-existing medical illness including renal, cardiac and liver disease * women for whom the study medication(s) are contraindicated or who have known allergic reactions to study medication(s) * women who have already taken part in this trial (i.e. cannot have more than one treatment cycle as a participant in this trial)

Keywords: ivf frozen embryo replacement
host response to urinary tract infection in women

Conditions: Urinary Tract Infection

Summary: this study is being done to identify those elements of the immune response that may predispose a woman to recurrent urinary tract infection. we suspect that lesser effectiveness of certain components of the host response will lead to recurrent urinary tract infection. we will also evaluate the role that the bladder reservoir may play in recurrent urinary tract infection.

procedures subjects will undergo once they have read and signed the consent are: questions about their medical and sexual history and current symptoms of urinary tract infection. they will be asked to provide a clean catch urine sample. we will collect periurethral, vaginal and rectal swabs. blood will collected. they will be given a diary to take home and record all episodes of sexual intercourse, contraceptive use, vaginal and urinary symptoms and medication use. they will be given standard treatment for the current urinary tract infection. follow-up visits will be scheduled 2 weeks,one month,two month and three month after initial visit.

Eligibility criteria:
inclusion criteria: * female * age 18-49 years * able to provide written informed consent * diagnosis of acute cystitis with symptoms for fewer than 7 days exclusion criteria: * not pregnant or planning pregnancy in next 3 months * no chronic illness requiring medical supervision (e.g. diabetes mellitus) * no known anatomic or functional abnormalities of the urinary tract * no signs or symptoms suggestive of pyelonephritis (flank pain or tenderness, temperature over 100 degrees f, nausea or vomiting)

Keywords: current symptoms of urinary tract infection
a phase 2 trial of amg 706 or bevacizumab in combination with chemo for advanced nsclc

Conditions: Advanced Non-squamous NSCLC

Summary: the purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus amg 706 arm (arm a and b) and paclitaxel/carboplatin plus bevacizumab arm (arm c) in subjects with advanced non-squamous nsclc.


Eligibility criteria:
inclusion criteria: * men or women 18 years or older with histologically or cytologically confirmed advanced non-squamous nsclc (unresectable stage iiib with pericardial or pleural effusion or stage iv/recurrent) * measureable disease per recist criteria modified * ecog performance status of 0 or 1 * ability to take oral medications * competent to give written informed consent exclusion criteria: * current or prior history of cns metastases * any prior chemotherapy for advanced nsclc * history of pulmonary hemorrhage or gross hemoptysis within 6 months prior to randomization * prior targeted therapies * known history of allergy or hypersensitivity to paclitaxel or carboplatin * history of arterial or venous thrombosis within 52 weeks prior to randomization * history of bleeding diathesis or non-pulmonary bleeding within 14 days prior to randomization * peripheral neuropathy \> grade 1 per ctcae version 3.0 * myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral vascular disease, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization * any kind of disorder that compromises the ability of the subject to comply with the study procedures * uncontrolled hypertension as defined by resting blood pressure \> 150/90 mm hg. anti-hypertensive medications are allowed if hypertension is stably controlled at the time of randomization. * participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization * pregnant or breast feeding women * known to be hiv, hepatitis b surface antigen, or hepatitis c positive

Keywords: amg 706 bevacizumab paclitaxel and carboplatin randomized non-small cell lung cancer
management of patients with atrial fibrillation undergoing coronary artery stenting

Conditions: Atrial Fibrillation; Oral Anticoagulation; Percutaneous Coronary Intervention

Summary: treatment of patients suffering from atrial fibrillation pose problems when percutaneous coronary intervention with stent implantation (pci-s) is performed. in the absence of solid evidence-based data, no definite recommendations for the management of this patient subset are currently given in the guidelines on percutaneous coronary intervention issued by the most prominent cardiology associations. the management of the antithrombotic treatment before invasive cardiac procedures is also incompletely defined. in this study we aim to determine in patients with atrial fibrillation undergoing pci-s: 1. the contemporary antithrombotic management; 2. the relative safety and efficacy of the various post-pci antithrombotic regimens; 3. the safety and efficacy of drug-eluting stents (des), bare-metal stents (bms), and bioactive stents (bas); 4. the safety of various periprocedural antithrombotic strategies including glycoprotein iib/iiia inhibitors and bivalirudin; 5. safety and efficacy of radial vs femoral approach.

afcas study is an observational, multi-center, prospective registry including patients with atrial fibrillation undergoing pci-s. follow-up time is 12 months. primary end points are major hemorrhagic and thrombotic/thromboembolic complications including cardiac death and secondary endpoints are major adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death), stent thrombosis and major/non major hemorrhagic complications. clinical follow-up will be completed for all patients via telephone, or clinic visits scheduled at 1, 3, 6, and 12 months after pci-s. the 1 and 6 months visits are optional. the patients will be asked about their clinical outcomes, hospitalizations and medications. any additional information needed, such as specific mortality, will be obtained by contacting one of the patient's physicians or other health care professional or from death certificates. crfs will be completed and faxed without delays after discharge, and after each follow up visit. recruitment will take approximately 12 months. follow-up will be 12 months for each patient.

Eligibility criteria:
inclusion criteria: * patients with atrial fibrillation who undergo pci. exclusion criteria: * because of the observational design, no exclusion criteria are provided.

Keywords: atrial fibrillation oral anticoagulation percutaneous coronary intervention
wumeiwan jiawei fang use in patients with blepharospasm

Conditions: Dry Eye Syndromes; Meige Syndrome; Blepharospasm; Hyperactivity

Summary: to evaluate the efficacy and safety of jing fang wu mei wan jiawei fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.

idiopathic blepharospasm is an idiopathic dysfunction characterized by involuntary spasms of the eyelids bilaterally that interfere with visual function and cause ocular discomfort. the incidence has increased each year in recent years, and the disease may present with persistent eye closure or even functional blindness in advanced stages. in some patients, the disease may be associated with submandibular dystonia, known as meige's syndrome. currently, the disease is treated symptomatically. such as oral.these treatments not only have large side effects, but also make it difficult to relieve the patient of multiple lesions in the eyes, face and tongue. chinese medicine has unique advantages in treating this disease, highlighting the overall diagnosis and solving different parts of the disease in an integrated manner. wu mei wan is a traditional chinese medicine prescription, and our team has been using wu mei wan jia wei fang for the treatment of meige syndrome since 2009 under the leadership of gao jiansheng, a famous chinese medicine teacher in the capital, and found significant therapeutic effects in preliminary clinical observation, but there is a lack of large sample of randomized controlled clinical studies. in this study, we propose to systematically observe the efficacy of traditional chinese medicine in the treatment of idiopathic blepharospasm by using the traditional sutra formula for idiopathic blepharospasm as a test group and local botulinum toxin a injection as a control group, and to scientifically evaluate the efficacy of the wu mei wan jia wei fang in the treatment of idiopathic blepharospasm.the results were evaluated in order to provide new treatment options for the clinical management of idiopathic blepharospasm (including meige syndrome) and to benefit more patients.

Eligibility criteria:
inclusion criteria: 1. idiopathic blepharospasm met the diagnostic criteria. 2. the age ranges from 18 to 80 years. 3. liver yang deficiency,mixed syndrome of cold and heat. 4. signed informed consent exclusion criteria: 1. secondary blepharospasm due to keratoconjunctivitis, trichiasis, and blepharitis. 2. open eyelid disuse. 3. hemifacial spasm. 4. the patient had undergone eye surgery in the previous 6 months. 5. allergic to the ingredients in the medicine. 6. corneal lenses were worn during the study. 7. a woman who is pregnant or breastfeeding. 8. combined with cardiovascular, cerebrovascular,liver and kidney function, hematopoietic system serious primary disease, mental patients, combined with stroke patients. 9. at the same time, use drugs that interfere with the evaluation of drug efficacy. 10. idiopathic blepharospasm is treated with other drugs.

Keywords: wumeiwan jiawei fang blepharospasm meige syndrome
efficacy of a resources activation treatment on tic-symptoms

Conditions: Tic-Disorder

Summary: the main purpose of this study is to evaluate the efficacy of a resources activation based treatment programme in children and adolescents aged 8 to 18 years with tic disorders.

the main purpose of this study is to evaluate the efficacy of an intervention aimed at the activation of resources for children and adolescents with tic disorders. the activation of resources treatment programme was developed at department of child and adolescent psychiatry and psychotherapy at the university of cologne and is currently evaluated in different studies.

Eligibility criteria:
inclusion criteria: * 8-18 years * diagnosis of chronic motor or vocal tic (f95.1) or tourette-syndrome (f95.2) * ygtss total score f95.2\>13, f95.1\>9 * tics are the main problems * iq\>80 * if medication, then has been stable for at least one months in medicated patients * no change in medication treatment is planned * ability to participate in weekly outpatient treatment * acceptance of randomization exclusion criteria: * diagnosis of autism spectrum disorder or psychosis * parallel continuous psychotherapy of tics or comorbid

Keywords: tic-disorder, tourette-disorder, resources activation